<p>Taysha Gene Therapies（納斯達克代碼：TSHA - 獲取免費報告）在週六發佈的研究報告中被華爾街 Zen 的投資分析師從 “賣出” 評級上調至 “持有” 評級。</p>
<p>獲取 <strong>Taysha Gene Therapies</strong> 的提醒：</p>
<ul>
<li>Neurogene 股票暴跌 44%：這家生物技術公司還有希望嗎？</li>
</ul>
<p>其他一些研究分析師最近也對 TSHA 發佈了報告。Raymond James Financial 於 10 月 21 日星期二開始對 Taysha Gene Therapies 的股票進行覆蓋。他們對該股票設定了 “強力買入” 評級和 13.00 美元的目標價。JMP Securities 在 11 月 5 日星期三的研究報告中對 Taysha Gene Therapies 的股票設定了 8.00 美元的目標價。Weiss Ratings 在週一的研究報告中重新發布了 Taysha Gene Therapies 的 “賣出（d-）” 評級。花旗集團在 11 月 5 日星期三的研究報告中重申了 Taysha Gene Therapies 的 “跑贏大盤” 評級。最後，Robert W. Baird 在 10 月 2 日星期四的研究報告中將 Taysha Gene Therapies 的目標價從 7.00 美元上調至 12.00 美元，並給予該股票 “跑贏大盤” 評級。一位分析師給予該股票 “強力買入” 評級，十一位分析師給予 “買入” 評級，一位分析師給予 “賣出” 評級。根據 MarketBeat.com 的數據，該股票的平均評級為 “適度買入”，平均目標價為 10.42 美元。</p>
<p><strong>查看我們關於 TSHA 的最新研究報告</strong></p>
<h2>Taysha Gene Therapies 股票上漲 0.5%</h2>
<ul>
<li>3 只小盤股適合你的秋季購物清單</li>
</ul>
<p>Taysha Gene Therapies 的股票在週五開盤價為 5.79 美元。該股票的 50 日移動平均線為 4.69 美元，200 日移動平均線為 3.47 美元。Taysha Gene Therapies 的一年低點為 1.05 美元，一年高點為 5.95 美元。該公司的市值為 15.9 億美元，市盈率為-17.55，貝塔係數為 1.06。該公司的債務與股本比率為 0.23，流動比率為 10.48，速動比率為 10.48。</p>
<p>Taysha Gene Therapies（納斯達克代碼：TSHA - 獲取免費報告）最近在 11 月 4 日星期二發佈了季度財報。公司報告每股收益（EPS）為（0.09 美元），符合市場共識預期（0.09 美元）。Taysha Gene Therapies 的股本回報率為-67.26%，淨利潤率為-1,144.97%。股票研究分析師預計 Taysha Gene Therapies 在本年度將發佈-0.35 的每股收益。</p>
<h2>Taysha Gene Therapies 的內部買賣情況</h2>
<p>在相關消息中，內部人士 Sukumar Nagendran 於 12 月 1 日星期一出售了 260,047 股公司的股票。股票以平均價格 4.51 美元出售，總價值為 1,172,811.97 美元。交易後，內部人士持有公司 1,006,439 股股票，價值約為 4,539,039.89 美元。此次交易代表其持股比例下降了 20.53%。該出售在與證券交易委員會的法律文件中披露，相關信息可通過 SEC 網站訪問。3.78% 的股票由公司內部人士持有。</p>
<h2>Taysha Gene Therapies 的機構交易情況</h2>
<p>一些對沖基金和其他機構投資者最近增加或減少了對 TSHA 的持股。先鋒集團在第三季度將其在 Taysha Gene Therapies 的持股增加了 17.9%。先鋒集團目前擁有 12,849,613 股公司股票，價值 42,018,000 美元，此前在上個季度又購買了 1,955,486 股。Octagon Capital Advisors LP 在第二季度將其在 Taysha Gene Therapies 的持股增加了 17.7%。Octagon Capital Advisors LP 目前擁有 12,592,500 股公司股票，價值 29,089,000 美元，此前在上個季度又購買了 1,892,500 股。Jefferies Financial Group Inc. 在第二季度將其在 Taysha Gene Therapies 的持股增加了 4,105.3%。Jefferies Financial Group Inc. 目前擁有 10,313,733 股公司股票，價值 23,825,000 美元，此前在上個季度又購買了 10,068,479 股。Vestal Point Capital LP 在第三季度將其在 Taysha Gene Therapies 的持股增加了 83.3%。Vestal Point Capital LP 目前擁有 5,500,000 股公司股票，價值 17,985,000 美元，此前在上個季度又收購了 2,500,000 股。最後，Polar Capital Holdings Plc 在第三季度將其在 Taysha Gene Therapies 的持股增加了 5.9%。Polar Capital Holdings Plc 目前擁有 5,293,879 股公司股票，價值 17,311,000 美元，此前在上個季度又收購了 293,879 股。77.70% 的股票由機構投資者持有。</p>
<h2>Taysha Gene Therapies 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Taysha Gene Therapies, Inc. 是一家基因治療公司，專注於開發和商業化基於腺病毒相關病毒的基因治療，用於治療中樞神經系統的單基因疾病。它主要開發 TSHA-120 用於治療巨軸神經病；TSHA-102 用於治療 Rett 綜合症；TSHA-121 用於治療 CLN7 疾病；TSHA-118 用於治療 CLN1 疾病；TSHA-105 用於治療 SLC13A5 缺乏症；TSHA-113 用於治療 tauopathies；TSHA-106 用於治療 Angelman 綜合症；TSHA-114 用於治療脆性 X 綜合症；以及 TSHA-101 用於治療 GM2 神經節苷脂症。</p>
<h2>另見</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Taysha Gene Therapies</li>
<li>掌握紀律：克服交易中的情緒挑戰</li>
<li>Synopsys 看到樂觀轉變，因 Ansys 整合推動增長</li>
<li>如何最有效地使用 MarketBeat 財報篩選器</li>
<li>你能給自己最好的節日禮物是什麼？Costco 股票</li>
<li>現在購買的三隻最佳金融科技股票</li>
<li>為什麼 Zscaler 股票在經歷 30% 拋售後可能準備反彈</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFNIQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFNIQQ"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 Taysha Gene Therapies 嗎？</h2>
<p>在考慮 Taysha Gene Therapies 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户在更廣泛市場注意到之前購買的股票……而 Taysha Gene Therapies 並不在名單上。</p>
<p>雖然 Taysha Gene Therapies 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

TSHA

<p>華爾街禪將 Taysha Gene Therapies（納斯達克代碼：TSHA）的評級從 “賣出” 上調至 “持有”。其他分析師的評級各不相同，有的給予 “強烈買入” 和 “跑贏大盤” 的評級。該股票開盤價為 5.79 美元，市值為 15.9 億美元。包括先鋒集團和傑富瑞在內的機構投資者已增加了對該公司的持股。內部交易活動有所增加，內部人士進行了大額出售。該公司專注於單基因疾病的基因療法</p>

<p>Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) was upgraded by investment analysts at Wall Street Zen from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research note issued on Saturday.</p>
<div class="lb-trans"><p>Taysha Gene Therapies（納斯達克代碼：TSHA - 獲取免費報告）在週六發佈的研究報告中被華爾街 Zen 的投資分析師從 “賣出” 評級上調至 “持有” 評級。</p>
</div><p>Get <strong>Taysha Gene Therapies</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Taysha Gene Therapies</strong> 的提醒：</p>
</div><ul>
<li>Neurogene Stock Plummets 44%: Is All Hope Lost for This Biotech?&#34;</li>
</ul>
<div class="lb-trans"><ul>
<li>Neurogene 股票暴跌 44%：這家生物技術公司還有希望嗎？</li>
</ul>
</div><p>A number of other research analysts also recently issued reports on TSHA. Raymond James Financial began coverage on shares of Taysha Gene Therapies in a research report on Tuesday, October 21st. They set a &#34;strong-buy&#34; rating and a $13.00 target price on the stock. JMP Securities set a $8.00 price target on shares of Taysha Gene Therapies in a research note on Wednesday, November 5th. Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Taysha Gene Therapies in a research report on Monday. Citigroup restated an &#34;outperform&#34; rating on shares of Taysha Gene Therapies in a research note on Wednesday, November 5th. Finally, Robert W. Baird upped their price target on Taysha Gene Therapies from $7.00 to $12.00 and gave the stock an &#34;outperform&#34; rating in a research note on Thursday, October 2nd. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of &#34;Moderate Buy&#34; and an average price target of $10.42.</p>
<div class="lb-trans"><p>其他一些研究分析師最近也對 TSHA 發佈了報告。Raymond James Financial 於 10 月 21 日星期二開始對 Taysha Gene Therapies 的股票進行覆蓋。他們對該股票設定了 “強力買入” 評級和 13.00 美元的目標價。JMP Securities 在 11 月 5 日星期三的研究報告中對 Taysha Gene Therapies 的股票設定了 8.00 美元的目標價。Weiss Ratings 在週一的研究報告中重新發布了 Taysha Gene Therapies 的 “賣出（d-）” 評級。花旗集團在 11 月 5 日星期三的研究報告中重申了 Taysha Gene Therapies 的 “跑贏大盤” 評級。最後，Robert W. Baird 在 10 月 2 日星期四的研究報告中將 Taysha Gene Therapies 的目標價從 7.00 美元上調至 12.00 美元，並給予該股票 “跑贏大盤” 評級。一位分析師給予該股票 “強力買入” 評級，十一位分析師給予 “買入” 評級，一位分析師給予 “賣出” 評級。根據 MarketBeat.com 的數據，該股票的平均評級為 “適度買入”，平均目標價為 10.42 美元。</p>
</div><p><strong>View Our Latest Research Report on TSHA</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 TSHA 的最新研究報告</strong></p>
</div><h2>Taysha Gene Therapies Stock Up 0.5%</h2>
<div class="lb-trans"><h2>Taysha Gene Therapies 股票上漲 0.5%</h2>
</div><ul>
<li>3 Small-Cap Stocks For Your Fall Shopping List</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只小盤股適合你的秋季購物清單</li>
</ul>
</div><p>Shares of Taysha Gene Therapies stock opened at $5.79 on Friday. The stock's 50-day moving average is $4.69 and its 200 day moving average is $3.47. Taysha Gene Therapies has a one year low of $1.05 and a one year high of $5.95. The firm has a market cap of $1.59 billion, a price-to-earnings ratio of -17.55 and a beta of 1.06. The company has a debt-to-equity ratio of 0.23, a current ratio of 10.48 and a quick ratio of 10.48.</p>
<div class="lb-trans"><p>Taysha Gene Therapies 的股票在週五開盤價為 5.79 美元。該股票的 50 日移動平均線為 4.69 美元，200 日移動平均線為 3.47 美元。Taysha Gene Therapies 的一年低點為 1.05 美元，一年高點為 5.95 美元。該公司的市值為 15.9 億美元，市盈率為-17.55，貝塔係數為 1.06。該公司的債務與股本比率為 0.23，流動比率為 10.48，速動比率為 10.48。</p>
</div><p>Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last issued its quarterly earnings results on Tuesday, November 4th. The company reported ($0.09) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.09). Taysha Gene Therapies had a negative return on equity of 67.26% and a negative net margin of 1,144.97%. Equities research analysts anticipate that Taysha Gene Therapies will post -0.35 EPS for the current year.</p>
<div class="lb-trans"><p>Taysha Gene Therapies（納斯達克代碼：TSHA - 獲取免費報告）最近在 11 月 4 日星期二發佈了季度財報。公司報告每股收益（EPS）為（0.09 美元），符合市場共識預期（0.09 美元）。Taysha Gene Therapies 的股本回報率為-67.26%，淨利潤率為-1,144.97%。股票研究分析師預計 Taysha Gene Therapies 在本年度將發佈-0.35 的每股收益。</p>
</div><h2>Insider Buying and Selling at Taysha Gene Therapies</h2>
<div class="lb-trans"><h2>Taysha Gene Therapies 的內部買賣情況</h2>
</div><p>In related news, insider Sukumar Nagendran sold 260,047 shares of the firm's stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $4.51, for a total value of $1,172,811.97. Following the transaction, the insider owned 1,006,439 shares of the company's stock, valued at approximately $4,539,039.89. This trade represents a 20.53% decrease in their position. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which can be accessed through the SEC website. 3.78% of the stock is owned by corporate insiders.</p>
<div class="lb-trans"><p>在相關消息中，內部人士 Sukumar Nagendran 於 12 月 1 日星期一出售了 260,047 股公司的股票。股票以平均價格 4.51 美元出售，總價值為 1,172,811.97 美元。交易後，內部人士持有公司 1,006,439 股股票，價值約為 4,539,039.89 美元。此次交易代表其持股比例下降了 20.53%。該出售在與證券交易委員會的法律文件中披露，相關信息可通過 SEC 網站訪問。3.78% 的股票由公司內部人士持有。</p>
</div><h2>Institutional Trading of Taysha Gene Therapies</h2>
<div class="lb-trans"><h2>Taysha Gene Therapies 的機構交易情況</h2>
</div><p>A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TSHA. Vanguard Group Inc. lifted its holdings in shares of Taysha Gene Therapies by 17.9% in the third quarter. Vanguard Group Inc. now owns 12,849,613 shares of the company's stock valued at $42,018,000 after purchasing an additional 1,955,486 shares in the last quarter. Octagon Capital Advisors LP grew its holdings in Taysha Gene Therapies by 17.7% during the second quarter. Octagon Capital Advisors LP now owns 12,592,500 shares of the company's stock worth $29,089,000 after buying an additional 1,892,500 shares in the last quarter. Jefferies Financial Group Inc. raised its position in Taysha Gene Therapies by 4,105.3% in the 2nd quarter. Jefferies Financial Group Inc. now owns 10,313,733 shares of the company's stock valued at $23,825,000 after buying an additional 10,068,479 shares during the last quarter. Vestal Point Capital LP lifted its stake in Taysha Gene Therapies by 83.3% during the 3rd quarter. Vestal Point Capital LP now owns 5,500,000 shares of the company's stock valued at $17,985,000 after acquiring an additional 2,500,000 shares in the last quarter. Finally, Polar Capital Holdings Plc boosted its holdings in Taysha Gene Therapies by 5.9% during the 3rd quarter. Polar Capital Holdings Plc now owns 5,293,879 shares of the company's stock worth $17,311,000 after acquiring an additional 293,879 shares during the last quarter. 77.70% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>一些對沖基金和其他機構投資者最近增加或減少了對 TSHA 的持股。先鋒集團在第三季度將其在 Taysha Gene Therapies 的持股增加了 17.9%。先鋒集團目前擁有 12,849,613 股公司股票，價值 42,018,000 美元，此前在上個季度又購買了 1,955,486 股。Octagon Capital Advisors LP 在第二季度將其在 Taysha Gene Therapies 的持股增加了 17.7%。Octagon Capital Advisors LP 目前擁有 12,592,500 股公司股票，價值 29,089,000 美元，此前在上個季度又購買了 1,892,500 股。Jefferies Financial Group Inc. 在第二季度將其在 Taysha Gene Therapies 的持股增加了 4,105.3%。Jefferies Financial Group Inc. 目前擁有 10,313,733 股公司股票，價值 23,825,000 美元，此前在上個季度又購買了 10,068,479 股。Vestal Point Capital LP 在第三季度將其在 Taysha Gene Therapies 的持股增加了 83.3%。Vestal Point Capital LP 目前擁有 5,500,000 股公司股票，價值 17,985,000 美元，此前在上個季度又收購了 2,500,000 股。最後，Polar Capital Holdings Plc 在第三季度將其在 Taysha Gene Therapies 的持股增加了 5.9%。Polar Capital Holdings Plc 目前擁有 5,293,879 股公司股票，價值 17,311,000 美元，此前在上個季度又收購了 293,879 股。77.70% 的股票由機構投資者持有。</p>
</div><h2>Taysha Gene Therapies Company Profile</h2>
<div class="lb-trans"><h2>Taysha Gene Therapies 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.</p>
<div class="lb-trans"><p>Taysha Gene Therapies, Inc. 是一家基因治療公司，專注於開發和商業化基於腺病毒相關病毒的基因治療，用於治療中樞神經系統的單基因疾病。它主要開發 TSHA-120 用於治療巨軸神經病；TSHA-102 用於治療 Rett 綜合症；TSHA-121 用於治療 CLN7 疾病；TSHA-118 用於治療 CLN1 疾病；TSHA-105 用於治療 SLC13A5 缺乏症；TSHA-113 用於治療 tauopathies；TSHA-106 用於治療 Angelman 綜合症；TSHA-114 用於治療脆性 X 綜合症；以及 TSHA-101 用於治療 GM2 神經節苷脂症。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Taysha Gene Therapies</li>
<li>Mastering Discipline: Overcoming Emotional Challenges In Trading</li>
<li>Synopsys Sees Bullish Shift as Ansys Integration Drives Growth</li>
<li>How to Most Effectively Use the MarketBeat Earnings Screener</li>
<li>The Best Holiday Present You Can Give Yourself? Costco Stock</li>
<li>The 3 Best Fintech Stocks to Buy Now</li>
<li>Why Zscaler Stock Could Be Ready to Bounce After a 30% Selloff</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Taysha Gene Therapies</li>
<li>掌握紀律：克服交易中的情緒挑戰</li>
<li>Synopsys 看到樂觀轉變，因 Ansys 整合推動增長</li>
<li>如何最有效地使用 MarketBeat 財報篩選器</li>
<li>你能給自己最好的節日禮物是什麼？Costco 股票</li>
<li>現在購買的三隻最佳金融科技股票</li>
<li>為什麼 Zscaler 股票在經歷 30% 拋售後可能準備反彈</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFNIQQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=TSHA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Taysha Gene Therapies Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Taysha Gene Therapies 嗎？</h2>
</div><p>Before you consider Taysha Gene Therapies, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Taysha Gene Therapies 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Taysha Gene Therapies wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户在更廣泛市場注意到之前購買的股票……而 Taysha Gene Therapies 並不在名單上。</p>
</div><p>While Taysha Gene Therapies currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Taysha Gene Therapies 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Taysha Gene Therapies（納斯達克股票代碼：TSHA）的評級在 Wall Street Zen 被上調至持有